Navigation Links
Medivation to Host Conference Call to Discuss Top-Line 12-Month,Results From Dimebon Alzheimer's Disease Study

SAN FRANCISCO, June 05, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that it will hold a teleconference at 8:30 a.m. Eastern time on Monday, June 11, to discuss top-line 12-month results from its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Dimebon(TM), its lead product candidate, in Alzheimer's disease.

Rachelle Doody, M.D., Ph.D., lead investigator for the study, will present the 12-month results for the first time at a scientific meeting at the 2007 Alzheimer's Association International Conference on Prevention of Dementia in Washington, D.C. Dr. Doody will present the data (abstract #S3-02-03, "Results of a One-Year Randomized, Placebo-Controlled Trial of Dimebon for the Treatment of Mild to Moderate Alzheimer's Disease") on Tuesday, June 12, at 10:00 a.m. Eastern time during the symposium session on "Emerging Compounds." Dr. Doody holds the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, in Houston.

The Alzheimer's Association, sponsor of the Prevention of Dementia conference, has selected the Dimebon data for inclusion in a news briefing to be held during the conference. That news briefing, which will focus on Alzheimer's disease therapies and be open to credentialed reporters, writers or editors from recognized external print, broadcast, syndicated or online news organizations, will take place at 12:00 p.m. Eastern time on Monday, June 11.

Teleconference/Webcast Details

To participate in the live call on Monday, June 11, at 8:30 a.m. Eastern time by telephone, please dial 800-565-5442 from the U.S. or 913-312-1298 internationally. A telephone replay will be available for seven days following the conclusion of the call by dialing 888-203-1112 from the U.S. or 719-457-0820 for international callers and entering passcode 4782383. Individuals interested in listening to the l ive call via webcast may do so by visiting A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company's financial and operating results.

CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,+1-415-543-3470 x201; or Jani Bergan of W eissComm Partners, +1-415-946-1064

Web site:

Ticker Symbol: (NASDAQ-NMS:MDVN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
3. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimers Disease Conference
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
8. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
9. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
11. Tercica to Present at Investment Conferences
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
(Date:11/25/2015)... Kitov Pharma ceuticals ... biopharmaceutical company focused on the development of therapeutic candidates ... announced the closing of its previously announced underwritten public ... each representing 20 ordinary shares of the Company, and ... and warrants were issued in a fixed combination of ...
(Date:11/25/2015)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer of ... Antonius Schuh, Ph.D., is scheduled to present a corporate ... Healthcare Conference. th Annual Piper Jaffray ... New York on Tuesday, December ... be available for one-on-one meetings during the conference. The ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... Dr. John Pierce, Medical Director at the Ageless Forever clinic in Las ... Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 offers men ... surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a home-use device ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, ... Two Organizations, One Beat ” campaign. The partnership between the two groups began in ... in MAP International’s cause. , MAP International was founded in 1954 and is an ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would ... OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE ... Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli ...
(Date:11/25/2015)... ... 25, 2015 , ... The McHenry County law firm of Botto Gilbert ... Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the ... App (2d) 130884WC. , According to court documents, Adcock testified that on May 10, ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) ... plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion of ... Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for his ...
Breaking Medicine News(10 mins):